Welcome to our dedicated page for SPEX news (Ticker: SPEX), a resource for investors and traders seeking the latest updates and insights on SPEX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SPEX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SPEX's position in the market.
AIkido Pharma Inc. (Nasdaq: AIKI) announced the appointment of Dr. Scott T. Tagawa to its Scientific Advisory Board. Dr. Tagawa is a highly regarded expert in oncology, serving as a Professor of Medicine and Urology at Weill Cornell Medicine. His extensive experience includes leading clinical trials focused on genitourinary cancers. CEO Anthony Hayes emphasized that Dr. Tagawa's expertise will significantly enhance the company's efforts in developing cancer therapies. AIkido continues to pursue innovative treatments, including those for pancreatic cancer and acute leukemia.
AIkido Pharma Inc. (Nasdaq: AIKI) has secured a $2 million Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., investing in advanced prostate cancer therapies. Convergent holds exclusive rights to patented technology for peptide receptor radionuclide therapy (PRRT) targeting prostate-specific membrane antigen (PSMA) on cancer cells. Two human clinical trials using Convergent's proprietary drug CONV 01-α are underway, with results expected in Q2 2021. The company anticipates additional trials using dual therapies beginning in February 2021, aiming to enhance treatment efficacy against prostate cancer.
